This snippet was from the Chairmans address at the AGM - Nov 24...

This snippet was from the Chairmans address at the AGM - Nov 24 last year.

I will now go on to summarize what we have learnt from our high level detailed discussions with the US multinational medical device companies. In short they see women’s pelvic floor issues as massive global market especially in first and second world countries. They have indicated that they want to be in this market. Currently there is no major multinational in this space. They see the PeriCoach as the only FDA, CE and TGA registered medical device in this field with strong clinical evidence from both Australia and North America supporting our medical claims for the PeriCoach. They see the PeriCoach as an alternative to pelvic floor surgery and in the most severe cases as an adjunct to surgery.

The version of the PeriCoach that they want is the V3 as the market potential for the V3 is far greater. Over the coming months we intend to release the V3 and to quickly gather as much clinical evidence as possible. This evidence on the V3 will supplement the mass of clinical evidence and data that we already have on the V2 PeriCoach. At this stage, we intend to reengage with the New York based Investment Banks with view to holding an auction. This auction will not only be for PeriCoach but also for the AutoStart Burette.

I will now address our endeavours to commercialise the ASB. In discussions with major burette multinationals it is clear that they will only licence our ASB technology if they can see that our burette is making inroads into their market share in first world hospitals. In June this year we announced the successful inclusion of our AutoStart Infusion system onto the Queensland Health purchasing schedule. It is our hope that the success of the ASB in Queensland Hospitals will be able to be used as a reference when licencing the ASB technology to major players in the US.

In July this year the AutoStart burette system was granted patent protection by the US Patent and Trademarks Office. This again is critical for a successful licence for the ASB technology. Before I finish this address I must make mention and thank all the Analytica staff who have worked so hard on the ASB and the PeriCoach. We have been able to develop the leading products in the world in both the women’s pelvic floor field and the IV infusions field. The PeriCoach is now being courted by some of the leading medical device companies on the planet.